Skip to main content
SpringerLink
Log in

Direct oral anticoagulants in patients with bioprosthetic heart valves

  • IM - COMMENTARY
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42(5):373–498

    Article  PubMed  Google Scholar 

  2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151

    Article  CAS  PubMed  Google Scholar 

  3. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104

    Article  CAS  PubMed  Google Scholar 

  4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992

    Article  CAS  PubMed  Google Scholar 

  5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891

    Article  CAS  PubMed  Google Scholar 

  6. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ et al (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369(13):1206–1214

    Article  CAS  PubMed  Google Scholar 

  7. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A et al (2022) Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med 387(11):978–988

    Article  CAS  PubMed  Google Scholar 

  8. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M et al (2015) Apixaban in comparison with warfarin in patients with atrial fibrillation and Valvular heart disease: findings from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) Trial. Circulation 132(8):624–632

    Article  CAS  PubMed  Google Scholar 

  9. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR et al (2014) Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 35(47):3377–3385

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF et al (2017) Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 69(11):1372–1382

    Article  PubMed  Google Scholar 

  11. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M et al (2016) Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy). Circulation 134(8):589–598

    Article  CAS  PubMed  Google Scholar 

  12. Renda G, Ricci F, Giugliano RP, De Caterina R (2017) Non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol 69(11):1363–1371

    Article  PubMed  Google Scholar 

  13. Galliazzo S, Pelitti V, Campiotti L et al (2023) Direct oral anticoagulants in patients with a left-sided bioprosthetic heart valve: a systematic review and meta-analysis. Intern Emerg Med 18:535–547. https://doi.org/10.1007/s11739-023-03208-9

  14. Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M et al (2017) Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 135(13):1273–1275

    Article  PubMed  Google Scholar 

  15. Guimaraes HP, Lopes RD, de Barros ESPGM, Liporace IL, Sampaio RO, Tarasoutchi F et al (2020) Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 383(22):2117–2126

    Article  CAS  PubMed  Google Scholar 

  16. Duan L, Doctor JN, Adams JL, Romley JA, Nguyen LA, An J et al (2021) Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves. Am J Cardiol 146:22–28

    Article  CAS  PubMed  Google Scholar 

  17. Duraes AR, de Souza RP, de Almeida NB, Albuquerque FP, de Bulhoes FV, de Souza Fernandes AM et al (2016) Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study. Drugs R D 16(2):149–154

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Piepiorka-Broniecka M, Michalski TA, Figatowski T, Wojtowicz A, Jurowiecki J, Stanska A et al (2022) NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement. Cardiol J 29(2):355–357

    Article  PubMed  PubMed Central  Google Scholar 

  19. Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S et al (2023) Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg 165(1):58-67.e4

    Article  PubMed  Google Scholar 

  20. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J et al (2022) 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 43(7):561–632

    Article  PubMed  Google Scholar 

  21. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR et al (1995) High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 25(5):1111–1119

    Article  CAS  PubMed  Google Scholar 

  22. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS et al (2012) Early anticoagulation of bioprosthetic aortic valves in older patients: results from the society of thoracic surgeons adult cardiac surgery national database. J Am Coll Cardiol 60(11):971–977

    Article  PubMed  Google Scholar 

  23. Merie C, Kober L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J et al (2012) Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 308(20):2118–2125

    Article  CAS  PubMed  Google Scholar 

  24. Rafiq S, Steinbruchel DA, Lilleor NB, Moller CH, Lund JT, Thiis JJ et al (2017) Antithrombotic therapy after bioprosthetic aortic valve implantation: Warfarin versus aspirin, a randomized controlled trial. Thromb Res 150:104–110

    Article  CAS  PubMed  Google Scholar 

  25. Calabro P, Gragnano F, Niccoli G, Marcucci R, Zimarino M, Spaccarotella C et al (2021) Antithrombotic therapy in patients undergoing transcatheter interventions for structural heart disease. Circulation 144(16):1323–1343

    Article  CAS  PubMed  Google Scholar 

  26. Van Mieghem NM, Unverdorben M, Hengstenberg C, Mollmann H, Mehran R, Lopez-Otero D et al (2021) Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med 385(23):2150–2160

    Article  PubMed  Google Scholar 

  27. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F et al (2021) 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation 143(5):e72–e227

    PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Institute of Cardiology, Department of Neuroscience, Imaging and Clinical Sciences, G. d’Annunzio University Chieti-Pescara, Via L. Polacchi 11, 66100, Chieti, Italy

    Giulia Renda

  2. Cardiology Unit - SS. Annunziata Hospital, Via Dei Vestini 31, 66100, Chieti, Italy

    Giulia Renda

Authors
  1. Giulia Renda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giulia Renda.

Ethics declarations

Conflict of interest

Giulia Renda declares: speaker/consultant fee from Astra Zeneca, Bayer, BMS-Pfizer, Boehringer Ingelheim, and Daiichi Sankyo; support for attending meetings and/or travel from Bayer, BMS-Pfizer, Daiichi Sankyo; participation on Advisory Board from Bayer.

Human and animal rights statement

This article does not contain any studies directly involving human participants, as it is a review of data already collected and published.

Informed consent

For this type of study, formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Renda, G. Direct oral anticoagulants in patients with bioprosthetic heart valves. Intern Emerg Med 18, 1269–1272 (2023). https://doi.org/10.1007/s11739-023-03288-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-023-03288-7

Keywords

Search

Navigation